A Phase 2 interventional study of COLLAGENASE CLOSTRIDIUM HISTOLYTICUM and Placebo Comparator in Edematous Fibrosclerotic Panniculopathy and Cellulite, sponsored by Endo Pharmaceuticals. Completed at 16 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-06.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Microbial Collagenase in Cellulite — none open to participants now, none under way, none of them phase 3. Microbial Collagenase · Cellulite.
Among the 15 studies testing Microbial Collagenase in Cellulite, this one is the 4th largest by enrollment, is one of 2 that started in 2016, is one of 8 in phase 2, and was the 3rd registered.
71 studies on the registry are indexed under Cellulite; 3 are open to participants now.
Browse Cellulite studies →None of the 15 studies testing Microbial Collagenase in Cellulite is open now. The open studies under Cellulite, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 1 Cellulite study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 375 is above the median of 34 across 65 interventional studies indexed under Cellulite.
Median enrollment 150 across the 15 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
18 studies in Cellulite by Keenova Therapeutics plc: none open now, none under way, none of them phase 3. Of 18 finished, 14 (78%) have results posted.
Among the 18 studies in Cellulite by Keenova Therapeutics plc, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2016, is one of 8 in phase 2, and was the 3rd registered.
Keenova Therapeutics plc’s Cellulite studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Microbial Collagenase in Cellulite, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keenova Therapeutics plc’s 18 in Cellulite:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the safety, effectiveness, and immunogenicity of EN3835 in the treatment of adult women with Edematous Fibrosclerotic Panniculopathy (Commonly known as Cellulite).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Screening visit, have at least 1 quadrant with:
At Day 1 visit, have an assigned quadrant with:
Exclusion Criteria:
Has any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
Biological: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Placebo
Biological: Placebo Comparator
Injectable intervention
Also known as: Xiaflex
Percentage of Composite Responders of at Least 2-Level Improvement of Severity
Percentage of composite responders defined as subjects with an improvement from baseline of at least 2-levels of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement on each scale for example would represent a change from a 4 (severe) to a 2 (mild). In order to be considered a responder a subject needs to have at least a 2-level improvement on both scales.
Time frame: Baseline, Day 71
Percentage of Composite Responders of at Least 1-Level Improvement of Severity
Percentage of composite responders defined as subjects with improvement from baseline of at least 1-level of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement on each scale for example would represent a change from a 4 (severe) to a 3 (moderate). In order to be considered a responder a subject needs to have at least a 1-level improvement on both scales.
Time frame: Baseline, Day 71
CR-PCSS Responder Analysis: 2-Levels of Severity
Percentage of subjects with improvement from baseline of at least 2-levels of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).
Time frame: Baseline, Day 71
CR-PCSS Responder Analysis: 1-Level of Severity
Percentage of subjects with improvement from baseline of at least 1-level of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).
Time frame: Baseline, Day 71
CR-PCSS Change From Baseline
The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.
Time frame: Baseline, Day 71
PR-PCSS Responder Analysis: 2-Levels of Severity
Percentage of subjects with improvement from baseline of at least 2-levels of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).
Time frame: Baseline, Day 71
PR-PCSS Responder Analysis: 1-Level of Severity
Percentage of subjects with improvement from baseline of at least 1-level of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).
Time frame: Baseline, Day 71
PR-PCSS Change From Baseline
The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.
Time frame: Baseline, Day 71
Investigator Assessment of Improvement Based on the Investigator Global Aesthetic Improvement Scale (I-GAIS)
On Day 71, the Investigator determined the degree of improvement from baseline in the treated area using the 7-point I-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3).
Time frame: Day 71
Subject Assessment of Improvement Based on the Subject Global Aesthetic Improvement Scale (S-GAIS)
At Day 71, subjects were asked to rate their opinion of the overall improvement of their treated area using the 7-point S-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3)
Time frame: Day 71
Subject Satisfaction Assessment Based on the the Subject Satisfaction Scale
At Day 71, subjects were asked to rate their satisfaction with cellulite treatment using the 5-point subject satisfaction scale. Ratings could be satisfied (+1), very satisfied (+2), neither satisfied nor dissatisfied (0), or dissatisfied (-1), very dissatisfied (-2).
Time frame: Day 71
Change in the Hexsel Cellulite Severity Scale (CSS) Total Score
Investigator used the Hexsel CSS to assess the severity of cellulite. The total score could range from 0 (no cellulite) to 15 (extremely severe cellulite). Negative change in Hexsel CSS total score indicates an improvement in cellulite severity
Time frame: Baseline, Day 71
| Milestone | EN3835 0.84 mg | Placebo |
|---|---|---|
| Started | 189 | 186 |
| Completed | 168 | 182 |
| Not completed | 21 | 4 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Lost to follow-up | 6 | 2 |
| Withdrew: Withdrawal by subject | 7 | 1 |
| Withdrew: Administrative | 1 | 0 |
Percentage of composite responders defined as subjects with an improvement from baseline of at least 2-levels of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement on each scale for example would represent a change from a 4 (severe) to a 2 (mild). In order to be considered a responder a subject needs to have at least a 2-level improvement on both scales.
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| Percentage of Composite Responders of at Least 2-Level Improvement of Severity | 20 | 3 |
Percentage of composite responders defined as subjects with improvement from baseline of at least 1-level of severity on each, the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS), at Day 71 in the ITT population. The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement on each scale for example would represent a change from a 4 (severe) to a 3 (moderate). In order to be considered a responder a subject needs to have at least a 1-level improvement on both scales.
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| Percentage of Composite Responders of at Least 1-Level Improvement of Severity | 79 | 33 |
Percentage of subjects with improvement from baseline of at least 2-levels of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the Investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| CR-PCSS Responder Analysis: 2-Levels of Severity | 32 | 9 |
Percentage of subjects with improvement from baseline of at least 1-level of severity on the Investigator-rated Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) at Day 71.The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| CR-PCSS Responder Analysis: 1-Level of Severity | 96 | 53 |
The CR-PCSS is a photonumeric scale that was used by the investigator to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.
| units on a scale | EN3835 0.84 mg | Placebo |
|---|---|---|
| CR-PCSS Change From Baseline | -0.7 ± 0.83 | -0.3 ± 0.62 |
Percentage of subjects with improvement from baseline of at least 2-levels of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 2-level improvement would be for example a change from 4 (severe) to 2 (mild).
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| PR-PCSS Responder Analysis: 2-Levels of Severity | 51 | 24 |
Percentage of subjects with improvement from baseline of at least 1-level of severity on the subject-rated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) at Day 71.The PR-PCSS is a photonumeric scale that was used by the subject to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). A 1-level improvement would be for example a change from 4 (severe) to 3 (moderate).
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| PR-PCSS Responder Analysis: 1-Level of Severity | 128 | 95 |
The PR-PCSS is a photonumeric scale that was used by the subjects to evaluate cellulite ranging from 0 (none), 1 (almost none), 2 (mild), 3 (moderate), to 4 (severe). Change is Day 71 study visit rating minus baseline visit; negative values indicate a lessening in cellulite severity.
| units on a scale | EN3835 0.84 mg | Placebo |
|---|---|---|
| PR-PCSS Change From Baseline | -1.0 ± 0.89 | -0.7 ± 0.79 |
On Day 71, the Investigator determined the degree of improvement from baseline in the treated area using the 7-point I-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3).
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| Very Much Improved (3) | 6 | 2 |
| Much improved (2) | 40 | 15 |
| Improved (1) | 64 | 43 |
| No Change( 0) | 57 | 119 |
| Worse (-1) | 6 | 4 |
| Much worse (-2) | 2 | 0 |
| Very Much Worse (-3) | 0 | 0 |
| Not done | 2 | 1 |
At Day 71, subjects were asked to rate their opinion of the overall improvement of their treated area using the 7-point S-GAIS. Ratings could be improved (+1), much improved (+2), or very much improved (+3), or no change (0), or worse (-1), much worse (-2) or very much worse (-3)
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| Very Much Improved (3) | 21 | 11 |
| Much Improved (2) | 43 | 17 |
| Improved (1) | 64 | 52 |
| No change (0) | 38 | 97 |
| Worse (-1) | 6 | 5 |
| Much Worse (-2) | 3 | 0 |
| Very Much Worse (-3) | 0 | 0 |
| Not done | 2 | 2 |
At Day 71, subjects were asked to rate their satisfaction with cellulite treatment using the 5-point subject satisfaction scale. Ratings could be satisfied (+1), very satisfied (+2), neither satisfied nor dissatisfied (0), or dissatisfied (-1), very dissatisfied (-2).
| Participants | EN3835 0.84 mg | Placebo |
|---|---|---|
| Very Satisfied (2) | 41 | 25 |
| Satisfied (1) | 69 | 40 |
| Neither Satisfied nor Dissatisfied (0) | 45 | 82 |
| Dissatisfied (-1) | 11 | 18 |
| Very Dissatisfied (-2) | 9 | 16 |
| Not done | 2 | 3 |
Investigator used the Hexsel CSS to assess the severity of cellulite. The total score could range from 0 (no cellulite) to 15 (extremely severe cellulite). Negative change in Hexsel CSS total score indicates an improvement in cellulite severity
| units on a scale | EN3835 0.84 mg | Placebo |
|---|---|---|
| Change in the Hexsel Cellulite Severity Scale (CSS) Total Score | -1.7 ± 2.20 | -0.9 ± 2.00 |
Collected over Baseline, Day 71. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EN3835 0.84 mg | — | 1/189 (0.5%) | 148/189 (78.3%) |
| Placebo | — | 0/186 (0%) | 30/186 (16.1%) |
| Event | EN3835 0.84 mg | Placebo |
|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/189 | 0/186 |
| Event | EN3835 0.84 mg | Placebo |
|---|---|---|
| Injection site bruisingGeneral disorders | 142/189 | 25/186 |
| Injection site painGeneral disorders | 112/189 | 10/186 |
| Injection site noduleGeneral disorders | 27/189 | 0/186 |
| Injection site pruritusGeneral disorders | 21/189 | 1/186 |
| Injection site swellingGeneral disorders | 14/189 | 1/186 |
| Injection site indurationGeneral disorders | 11/189 | 0/186 |
| Injection site massGeneral disorders | 10/189 | 1/186 |
Analysis based on intent-to-treat (ITT) population; all randomized subjects who received at least 1 injection of study medication
| Age, Continuous(Participants) | EN3835 0.84 mg | Placebo | Total |
|---|---|---|---|
| Mean | 47.2 ± 11.21 | 45.8 ± 11.02 | 46.5 ± 11.13 |
| Age, Customized(Participants) | EN3835 0.84 mg | Placebo | Total |
|---|---|---|---|
| 18-<25 years | 8 | 9 | 17 |
| 25-34 years | 18 | 21 | 39 |
| 35-44 years | 46 | 47 | 93 |
| >=45 years | 117 | 109 | 226 |
| Sex: Female, Male(Participants) | EN3835 0.84 mg | Placebo | Total |
|---|---|---|---|
| Female | 189 | 186 | 375 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | EN3835 0.84 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 41 | 78 |
| Not Hispanic or Latino | 152 | 145 | 297 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | EN3835 0.84 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 15 | 26 | 41 |
| White | 167 | 157 | 324 |
| More than one race | 3 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | EN3835 0.84 mg | Placebo | Total |
|---|---|---|---|
| United States | 189 | 186 | 375 |
Plan to share: Yes
No publications or documents are linked to this record.
The record gives a start of Feb 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase